Apalutamide – 10 clinically important facts Review article

Article Sidebar

PDF


Published: Sep 30, 2021
DOI: https://doi.org/10.24292/01.OR.123300921.2
Keywords:
apalutamide, prostate cancer, nonmetastatic, metastatic, CRPC, CSPC

Main Article Content

Kajetan Juszczak
1. Department of Urology and Andrology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. 2. Department of Urology Memorial Rydygier Hospital, Cracow, Poland
Tomasz Drewa
1. Department of Urology and Andrology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. 2. Department of General and Oncological Urology, Nicolaus Copernicus Hospital, Torun, Poland

Abstract

Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over timeduring hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. Apalutamide is used in the treatment of patients with non-metastatic as well as metastatic prostate cancer. This article presents the most important clinical facts about apalutamide.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Juszczak K, Drewa T. Apalutamide – 10 clinically important facts. OncoReview [Internet]. 2021Sep.30 [cited 2024Nov.22];11(3(43):85-8. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1521
Issue
Vol 11 No 3(43) (2021)
Section
PERSONALIZED ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Mateo J, Fizazi K, Gillessen S et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019; 75(2): 285-93.
2. Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med. 2017; 7(9): a030452.
3. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer. 2010; 17(4): R305315.
4. Smith MR, Kabbinavar F, Saad F et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005; 23(13): 2918-25.
5. Whitney CA, Howard LE, Freedland SJ et al. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019; 22: 252-60.
6. Saad F, Cella D, Basch E et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018; 19: 1404-16.
7. Smith MR, Saad F, Chowdhury S et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021; 79(1): 150-8.
8. Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012; 72(6): 1494-503.
9. Smith MR, Saad F, Chowdhury S et al; SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378(15): 1408-18.
10. Charakterystyka produktu leczniczego ERLEADA® (apalutamid). Luty 2021.
11. Chi KN, Agarwal N, Bjartell A et al; TITAN Investigators. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019; 381(1): 13-24.